Carlisle Companies Declares Regular Quarterly Dividend
Get Alerts CSL Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 1.4%
Revenue Growth %: +10.0%
Join SI Premium – FREE
SCOTTSDALE, Ariz.--(BUSINESS WIRE)-- The Board of Directors of Carlisle Companies Incorporated (NYSE: CSL) has declared a dividend of $0.54 per share, payable on June 1, 2022, to shareholders of record at the close of business on May 17, 2022.
About Carlisle Companies Incorporated
Carlisle Companies Incorporated is a leading supplier of innovative Building Envelope products and energy-efficient solutions for customers creating sustainable buildings of the future. Through its construction materials businesses (CCM and CWT) and family of leading brands, Carlisle delivers innovative, labor-reducing and environmentally responsible products and solutions to customers through the Carlisle Experience. Over the life of a building, Carlisle’s products help drive lower greenhouse gas emissions, improve energy savings for building owners and operators, and increase a building’s resiliency to the elements. Driven by its strategic plan, Vision 2025, Carlisle is committed to generating superior shareholder returns and maintaining a balanced capital deployment approach, including investments in our businesses, strategic acquisitions, share repurchases and continued dividend increases. Carlisle also is a leading provider of products to the Aerospace, Medical Technologies and General Industrial markets through its Interconnect Technologies (CIT) and Fluid Technologies (CFT) business segments.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220503005032/en/
Jim Giannakouros, CFA
Vice President of Investor Relations
Carlisle Companies Incorporated
(480) 781-5135
[email protected]
Source: Carlisle Companies Incorporated
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 S
- Sonesitatug vedotin reduced the risk of death by 42% in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers in CLARITY-Gastric01
- Dogecoin Price Prediction: Can DOGE Reclaim $0.10 as Remittix Recruits Earn Testers for 18-22% APY?
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
DividendSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share